272 related articles for article (PubMed ID: 23588724)
1. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.
Hagiwara S; Kudo M; Osaki Y; Matsuo H; Inuzuka T; Matsumoto A; Tanaka E; Sakurai T; Ueshima K; Inoue T; Yada N; Nishida N
J Med Virol; 2013 Jun; 85(6):987-95. PubMed ID: 23588724
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
4. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
5. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
Shi M; Sun WL; Hua YY; Han B; Shi L
PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
[TBL] [Abstract][Full Text] [Related]
6. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
8. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
9. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
11. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
Chan HL; Wong VW; Chim AM; Choi PC; Chan HY; Hui AY; Wong GL; Sung JJ
Antivir Ther; 2007; 12(5):815-23. PubMed ID: 17713165
[TBL] [Abstract][Full Text] [Related]
12. The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.
Liu S; Zheng H; Huang Y; Li B; Dong Z
Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):304-308. PubMed ID: 26382279
[TBL] [Abstract][Full Text] [Related]
13. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
Hagiwara S; Nishida N; Watanabe T; Ida H; Sakurai T; Ueshima K; Takita M; Komeda Y; Nishijima N; Osaki Y; Kudo M
Antivir Ther; 2018; 23(6):513-521. PubMed ID: 29438098
[TBL] [Abstract][Full Text] [Related]
14. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.
Sung JJ; Wong ML; Bowden S; Liew CT; Hui AY; Wong VW; Leung NW; Locarnini S; Chan HL
Gastroenterology; 2005 Jun; 128(7):1890-7. PubMed ID: 15940624
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
18. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
Lu HY; Zhuang LW; Yu YY; Si CW
J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
[TBL] [Abstract][Full Text] [Related]
20. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
